Pre-made Erlizumab benchmark antibody (Whole mAb, anti-ITGB2 therapeutic antibody, Anti-CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-ITGB2 therapeutic antibody (Pre-made Erlizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab was developed by Genentech under a partnership with Roche to treat heart attack, stroke, and traumatic shock.[1]
| Products Name (INN Index) | Pre-Made Erlizumab Biosimilar, Whole Mab, Anti-Itgb2 Antibody: Anti-CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody |
|---|---|
| INN Name | erlizumab |
| Target | ITGB2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGB2 |
| Package |
